Poolbeg Pharma (POLB) H2 2025 earnings summary

Executive summary

• Advancing POLB 001, an oral p38 MAPK inhibitor for CRS prevention in cancer immunotherapy, and an oral GLP-1 program for obesity, leveraging encapsulation technology for improved delivery.

• Achieved Orphan Drug Designation from the FDA, multiple patent grants, and published positive peer-reviewed data.

• Strong momentum in partnering discussions with large and mid-size pharma, supported by compelling clinical and preclinical data.

• Experienced leadership and board with a track record of successful transactions and exits in life sciences.

• Financial runway secured into 2027, enabling execution of key clinical programs and flexibility for future transactions.

Financial highlights

• Ended 2025 with GBP 7.7 million in cash, supporting operations and clinical development, with runway into 2027.

• Raised GBP 4.865 million in an oversubscribed fundraising in June 2025.

• Received a GBP 3.4 million grant for CRS research in collaboration with University of Manchester and The Christie NHS Trust.

Outlook and guidance

• POLB 001 CRS prevention trial in multiple myeloma patients is fully prepared, with patient dosing imminent and interim data expected in summer/H2 2026.

• Oral GLP-1 clinical trial for obesity is set to commence in the second half of 2026, aiming for rapid completion and value creation.

• Multiple near-term clinical milestones anticipated, supporting partnering opportunities and potential transactions following clinical data readout.